Denosumab (Prolia®) for the treatment of osteoporosis

The Health Technology Assessment (HTA) aims to evaluate the safety, efficacy, cost-effectiveness and budgetary impact of treatment with Denosumab (Prolia®) compared to placebo, bisphosphonates and selective oestrogen receptor modulators (SERMs) in patients with osteoporosis.

Last modification 07.05.2021

Top of page


Federal Office of Public Health FOPH
Health insurance benefits Division
Health Technology Assessment Section
Schwarzenburgstrasse 157
3003 Berne
Tel. +41 58 469 17 33

Print contact